Genes encoding Phl p 5-specific antibody fragments ( Supplementary Table S1 ) have been selected by phage display technology [E1-E4] from combinatorial antibody libraries created from transcripts encoding allergic patients' IgE as found in peripheral blood B lineage cells.
SUPPLEMENTARY MATERIALS AND METHODS

Recombinant antibody fragments
Genes encoding Phl p 5-specific antibody fragments ( Supplementary Table S1 ) have been selected by phage display technology [E1-E4] from combinatorial antibody libraries created from transcripts encoding allergic patients' IgE as found in peripheral blood B lineage cells.
All these genes ( Supplementary Table S1 ) except one (clone 5) were obtained after selection in a form that encode a single chain fragment variable (scFv) product. A gene, optimised for production in human cells with respect to codon usage, encoding clone 5 in scFv format was synthesized by GenART (Invitrogen, Carlsbad, CA). The genetic origin and mutational status of the genes encoding the heavy chain variable domains of the originally isolated antibody fragments were re-analyzed using the IMGT V-QUEST web interface [E5] The first 23 nucleotides of the sequences were eliminated from the analysis as they are encoded for by PCR primers used in the process of creating the libraries from which the binders have been selected.
Production of scFv-Fc in HEK293 cell line
In order to produce scFv fused to the Fc fragment of human IgE and IgG 2 , the scFv-encoding gene sequence was digested with SfiI and NotI and ligated into a vector (pFUSE-hIgG-Fc2; kindly provided by Dr. Franck Perez (Institut Curie, CNRS UMR144, Paris, France)) carrying the gene encoding the second and third constant domains of human IgG 2 [E6] or a related vector encoding the second, third and fourth constant domains of IgE [E7] , respectively. A single clone carrying each sequence was identified and the correctness of the cloned gene was confirmed by gene sequencing (GATC Biotech, Konstanz, Germany). The plasmid was purified from Top 10 Escherichia coli cells (Invitrogen) using the Qiaprep Spin Miniprep Kit (Qiagen, Hilden, Germany) according to the manufacturer's description. The vector was transfected using Lipofectamin 2000 (Invitrogen) into 90% confluent HEK293 cells grown in MEM medium (Invitrogen) containing 10 % fetal calf serum (Invitrogen). ScFv-Fc fusion proteins (molecular weights approximately 110 kDa) were retrieved in the form of culture supernatants after 3 days of culture and used in that form. Clone 5 scFv-Fcε could for unknown reasons not be produced in this manner and this product is therefore excluded from all analysis. 4.2 scFv-Fc was poorly produced (<5µg/ml) and it could not reproducibly be implemented in several of the below described assays. It has therefore been excluded from such assays.
Production of the C-terminal domain of Phl p 5.0101 and mutated versions thereof
Genes encoding the C-terminal half (residues 181-312) of Phl p 5.0101 were synthesized (codon-optimised for protein production in Escherichia coli) and cloned into the pGEX-6P-1 vector (GE Healthcare, Chalfont St. Giles, United Kingdom) by GenART. Genes encoding mutated variants of this protein (each carrying one of the following mutations: K246A, K270A, K280A) were synthesized and cloned in the same way. These vectors were transformed into the E. coli T7 Express strain (New England Biolabs, Ipswich, MA). Production of the GSTfused proteins was induced with isopropyl β-D-1-thiogalactopyranoside (IPTG) in a growing culture at OD 600 ≈0.5. After 3 hours of culture at 37°C the cells were harvested by centrifugation at 7 500 x g for 12 minutes and treated with lysozyme (Sigma-Aldrich, St.
Louis, MO). Soluble proteins were purified using affinity chromatography with GSTrap FF columns (GE Healthcare) and dialyzed against PBS prior to use. ELISA Femto Maximum Substrate (Thermo Scientific). Absorbance and luminescence were read in a FLUO star OMEGA microtitreplate reader (BMG-Labtech, Ortenberg, Germany). In competition assays immobilized allergens were pre-incubated with scFv-Fc fusion proteins before being incubated with a scFv fused to an Fc of another isotype (IgE or IgG 2 ). Binding of the second antibody was finally assessed as described above.
Immunoassay to determine reactivity to recombinant allergens
Analysis of the inhibition of binding of scFv displayed on phage to immobilized allergen Phl p 5.0201 by soluble allergen derivatives (C-terminal domain or mutated versions thereof) was made by a similar methodology. In this case the phage solution was pre-incubated at 37°C for 1 h with different concentrations of soluble allergen or the C-terminal domains of Phl p 5.0201 prior to addition to a microtitre plate coated with.Phl p 5.0201. Detection of bound phages was performed as described above. ScFv p5b-7 (identical to p5-MA5) and scFv p5b-31 (identical to scFv 4.12 except for its use of a different light chain sequence) selected for binding to Phl p5.0201, both of which also cross-react to Phl p 5.0101) (data not shown) were used in this investigation.
Phl p 5 sandwich assay to assess epitope recognition
The relationship of epitopes detected by different binders was also assessed by a sandwich ELISA approach. Goat anti-human IgG (Invitrogen) was coated onto 96-well microtitre plates.
After washing as above, recombinant scFv-Fcγ2 (0.5 µg/ml) diluted in TPBSB buffer were added and plates were incubated for 1 h at 37°C. Unbound scFv-Fcγ2 was washed away and the wells were incubated for 1 h at 37°C with recombinant Phl p 5.0101 (0.5 µg/ml) in TPBSB buffer. After another wash step, recombinant scFv-Fcε (25 kU/L as determined by an ImmunoCAP IgE assay (Phadia AB, Uppsala, Sweden)) diluted in TPBSB buffer was added and plates were incubated for 1 h at 37°C. Finally, after washing, bound scFv-Fcε was detected with goat anti-human IgE as described above using luminescent substrate. 
Epitope mapping using peptide and allergen-specific anti-sera
Blocking serum IgE allergen binding with recombinant scFv-Fcγ2
The inhibitory capacity of recombinant antibody fragments on allergic patients IgE binding was studied by ELISA inhibition studies [E9-E11]. ELISA plates (MaxiSorp) were coated with Phl p 5.0101 (20 ng/well in 0.05 M sodium bicarbonate (pH 9.6) overnight. The plates were washed twice with PBST and blocked with PBST containing 1% BSA at 37°C for 3 h. After blocking, the wells were incubated overnight at 4°C with either 1) a mix of cell culture supernatants containing four human Phl p 5-specific scFv-Fcγ2 (clone 5, 4.3, 4.13 and P5-AB5), each binding an independent epitope (see Table 1 and Supplementary Figure S1 To further investigate binding of patients' IgE antibodies to Phl p 5 already bound to several scFv-Fc, allergen/scFv-Fcγ2 complexes were preformed in solution and then exposed to sera of grass pollen allergic patients. In detail, 5 µg/ml goat anti-human IgG (Invitrogen) in 0.05 M sodium bicarbonate (pH 9.6) was coated onto ELISA plates (MaxiSorp). The plates were washed twice with PBST and blocked with PBST containing 1% BSA at 37°C for 3 h. In parallel, complexes consisting of 0.1 µg/ml Phl p 5 and 3.5 µg/ml clone 5 or of 0.1 µg/ml Phl p 5 and a mixture of four scFv-Fcγ2 (clone 5, 4.3, 4.13 and p5-AB5, each at 3.5 µg/ml) were preformed in tubes at room temperature. These complexes were loaded onto wells containing immobilized anti-human IgG and incubated over night at 4°C. After washing five times with PBST, the plates were incubated in triplicates with sera from grass pollen allergic patients diluted 1:10 in PBST/0.5% BSA for 1 h at 37°C. Bound IgE antibodies were detected with an alkaline phosphatase-conjugated mouse monoclonal antihuman IgE antibody (BD Pharmingen), as described above.
Affinity determination
The affinity of scFv-Phl p 5.0101 interaction was determined using a surface plasmon resonance based methodology on the MASS-1 platform (Sierra Sensors, Hamburg, Germany). Briefly, a polyclonal goat anti-human IgG antiserum (Invitrogen) was immobilized onto a High Capacity Amine sensor (Sierra Sensors). was caught on the chip's B surface. Its A surface was run without immobilized scFv-Fcγ2 and used for background subtraction. PBS containing 0.005% Tween 20 was used as running buffer. Phl p 5.0101 (1.5-400 nM) was injected for 2 minutes over both surfaces with a flow rate of 25 µl/min. The dissociation phase was monitored for 5 minutes at the same flow rate. Flow channels were regenerated using 0.1 M HCl. Reaction rate kinetics and affinity constants were calculated using a 1:1 binding with mass transport limitations model using the AnalyserR2 version 0.1.5.0 software (Sierra Sensors). 
Supplementary Table S1. Genes encoding and summary of properties of Phl p 5-specific IgE a
